|
CA2019714A1
(en)
|
1989-06-27 |
1990-12-27 |
Richard A. Chizzonite |
Process for the determination of interleukins
|
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
|
AU5300299A
(en)
|
1998-08-21 |
2000-03-14 |
Yeda Research And Development Co. Ltd. |
Anti-inflammatory peptides derived from il-2 and analogues thereof
|
|
HUP0204475A2
(en)
|
2000-02-11 |
2003-04-28 |
Merck Patent Gmbh |
Enhancing the circulating half-life of antibody-based fusion proteins
|
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
DE60129695T2
(de)
|
2000-06-29 |
2008-06-05 |
Merck Patent Gmbh |
Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
|
|
PT1454138E
(pt)
|
2001-12-04 |
2012-03-28 |
Merck Patent Gmbh |
Imunocitoquinas com seletividade modulada
|
|
WO2005007121A2
(en)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Mutant interleukin-2(il-2) polypeptides
|
|
US8147832B2
(en)
|
2003-08-14 |
2012-04-03 |
Merck Patent Gmbh |
CD20-binding polypeptide compositions and methods
|
|
AU2013205042B2
(en)
*
|
2004-12-22 |
2016-05-12 |
Ambrx, Inc. |
Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
|
|
AU2006207987B2
(en)
|
2005-01-27 |
2011-09-15 |
Novartis Vaccines And Diagnostics Inc. |
Methods for treating renal cell carcinoma
|
|
US7667076B2
(en)
|
2005-09-14 |
2010-02-23 |
Regents Of The University Of California |
Amide forming chemical ligation
|
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
MX2011007647A
(es)
|
2009-01-21 |
2011-09-01 |
Amgen Inc |
Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
ES2866674T3
(es)
|
2010-11-12 |
2021-10-19 |
Nektar Therapeutics |
Conjugados de una fracción de IL-2 y un polímero
|
|
US9428567B2
(en)
|
2010-12-22 |
2016-08-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antagonists of interleukin-2 receptor
|
|
HUE029139T2
(hu)
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
|
EP2723380B1
(en)
|
2011-06-24 |
2019-08-21 |
Stephen D. Gillies |
Light chain immunoglobulin fusion proteins and methods of use thereof
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
EP3004062B1
(en)
|
2013-05-24 |
2017-07-19 |
SynAffix B.V. |
Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions
|
|
WO2015112016A1
(en)
|
2014-01-24 |
2015-07-30 |
Synaffix B.V. |
Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne
|
|
KR102042246B1
(ko)
|
2014-02-06 |
2019-11-28 |
에프. 호프만-라 로슈 아게 |
인터류킨-2 융합 단백질 및 이의 용도
|
|
MX385194B
(es)
|
2014-02-21 |
2025-03-14 |
Nektar Therapeutics India Pvt Ltd |
Agonistas il-2rbeta-selectivos en combinación con un anticuerpo anti-ctla-4 o un anticuerpo anti-pd-1.
|
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
WO2016025385A1
(en)
|
2014-08-11 |
2016-02-18 |
Delinia, Inc. |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
JP6800141B2
(ja)
|
2014-08-12 |
2020-12-16 |
マサチューセッツ インスティテュート オブ テクノロジー |
Ｉｌ−２およびインテグリン結合性ｆｃ融合タンパク質による相乗的な腫瘍処置
|
|
US20170224777A1
(en)
|
2014-08-12 |
2017-08-10 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
|
MY193723A
(en)
|
2014-08-29 |
2022-10-27 |
Hoffmann La Roche |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
|
KR102739782B1
(ko)
|
2015-09-11 |
2024-12-09 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
생물학적으로 관련된 직교 사이토카인/수용체 쌍
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
US10888603B2
(en)
|
2016-02-12 |
2021-01-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating cancer cells expressing tumor-associated integrins
|
|
JP6911044B2
(ja)
|
2016-03-16 |
2021-07-28 |
シェ、ヤンホイＸｉｅ Ｙａｎｈｕｉ |
呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン２の組合せ
|
|
KR102687530B1
(ko)
|
2016-05-04 |
2024-07-25 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
US11395853B2
(en)
|
2016-06-23 |
2022-07-26 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
|
|
WO2018002016A1
(en)
|
2016-06-28 |
2018-01-04 |
Ventana Medical Systems, Inc. |
Application of click chemistry for signal amplification in ihc and ish assays
|
|
US11077172B2
(en)
|
2016-11-08 |
2021-08-03 |
Delinia, Inc. |
IL-2 variants for the treatment of psoriasis
|
|
US20190275133A1
(en)
|
2016-11-10 |
2019-09-12 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
|
CU24483B1
(es)
|
2016-11-15 |
2020-04-02 |
Ct Inmunologia Molecular |
Método para incrementar los niveles de secreción de la interleucina-2
|
|
CN116970059A
(zh)
|
2016-12-22 |
2023-10-31 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
SG11201906682YA
(en)
*
|
2017-01-27 |
2019-08-27 |
Ngm Biopharmaceuticals Inc |
Glucagon receptor binding proteins and methods of use thereof
|
|
RU2761377C2
(ru)
|
2017-04-03 |
2021-12-07 |
Ф. Хоффманн-Ля Рош Аг |
Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
|
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
|
WO2019112852A1
(en)
|
2017-12-06 |
2019-06-13 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
JP2020521452A
(ja)
|
2017-05-24 |
2020-07-27 |
パンディオン・セラピューティクス・インコーポレイテッド |
標的化免疫寛容
|
|
AU2018287317B2
(en)
|
2017-06-19 |
2024-06-20 |
Medicenna Therapeutics Inc. |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|
|
US20190023760A1
(en)
|
2017-07-24 |
2019-01-24 |
Eth Zurich |
Method for preparing interleukin-2 or interleukin-2 analogues
|
|
WO2019028419A1
(en)
|
2017-08-03 |
2019-02-07 |
Synthorx, Inc. |
CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
|
|
EP3668548A2
(en)
|
2017-08-17 |
2020-06-24 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
|
US20200299349A1
(en)
|
2017-11-21 |
2020-09-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Partial agonists of interleukin-2
|
|
US11319355B2
(en)
*
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
|
CN111527109B
(zh)
|
2017-12-26 |
2024-11-01 |
南京金斯瑞生物科技有限公司 |
以抗体Fc区为骨架的融合蛋白二聚体及其应用
|
|
WO2019173832A2
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
EA202092489A1
(ru)
*
|
2018-05-21 |
2021-03-16 |
Нектар Терапьютикс |
СЕЛЕКТИВНЫЙ СТИМУЛЯТОР Treg RUR20kD-IL-2 И РОДСТВЕННЫЕ КОМПОЗИЦИИ
|
|
JP7637415B2
(ja)
*
|
2018-06-22 |
2025-02-28 |
キュージーン インコーポレイテッド |
インターロイキン－２バリアントおよびその使用方法
|
|
HRP20240016T1
(hr)
|
2018-09-11 |
2024-03-29 |
Ambrx, Inc. |
Konjugati polipeptida interleukina-2 i njihove uporabe
|
|
WO2020057646A1
(zh)
|
2018-09-21 |
2020-03-26 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
|
KR20260039812A
(ko)
|
2019-02-06 |
2026-03-20 |
신톡스, 인크. |
Il-2 콘쥬게이트 및 이의 사용 방법
|
|
EP3969051A1
(en)
|
2019-05-17 |
2022-03-23 |
Shenzhen Enduring Biotech, Ltd. |
Bispecific t-cell engager with cleavable cytokines for targeted immunotherapy
|
|
CN114728040A
(zh)
|
2019-06-14 |
2022-07-08 |
科优基因公司 |
新型白介素-2变体及其双功能融合分子
|
|
KR20220044534A
(ko)
|
2019-08-13 |
2022-04-08 |
엘피스 바이오파마슈티컬즈 |
조작된 인터류킨-2 수용체 베타 효능제
|
|
EP4013777A4
(en)
|
2019-08-15 |
2024-01-17 |
Cytimm Therapeutics, Inc. |
MODIFIED INTERLEUKIN 2 (IL-2) POLYPEPTIDES, CONJUGATES AND USES THEREOF
|
|
CN114555128A
(zh)
|
2019-08-15 |
2022-05-27 |
新索思股份有限公司 |
采用il-2缀合物的免疫肿瘤学组合疗法
|
|
CN114853874B
(zh)
*
|
2019-09-10 |
2024-05-17 |
中国医学科学院北京协和医院 |
靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
|
|
MX2022002740A
(es)
*
|
2019-09-10 |
2022-03-25 |
Synthorx Inc |
Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
|
|
MX2022007202A
(es)
|
2019-12-13 |
2022-10-07 |
Cugene Inc |
Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
|
|
US11633488B2
(en)
|
2020-01-10 |
2023-04-25 |
Bright Peak Therapeutics Ag |
Modified IL-2 polypeptides and uses thereof
|
|
AR121891A1
(es)
|
2020-04-22 |
2022-07-20 |
Merck Sharp & Dohme |
CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 bgᶜ Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO
|
|
US20230272001A1
(en)
|
2020-05-22 |
2023-08-31 |
Merck Sharp & Dohme Llc |
Novel processes for preparing conjugates of the il-2 protein
|
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
|
EP4281186A1
(en)
|
2021-01-22 |
2023-11-29 |
Elpis Biopharmaceuticals |
Anti-pd-l1 monoclonal antibodies and fusion proteins with interleukin-15 (il-15), interleukin-15 receptor 15 alpha or interleukin-2
|
|
WO2023281485A1
(en)
|
2021-07-09 |
2023-01-12 |
Bright Peak Therapeutics Ag |
Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
|
|
US20230201364A1
(en)
|
2021-07-09 |
2023-06-29 |
Bright Peak Therapeutics Ag |
Antibody conjugates and manufacture thereof
|
|
US20230201365A1
(en)
|
2021-07-09 |
2023-06-29 |
Bright Peak Therapeutics Ag |
Modified cd20 antibodies and uses thereof
|
|
US20230181754A1
(en)
|
2021-07-09 |
2023-06-15 |
Bright Peak Therapeutics Ag |
Modified checkpoint inhibitors and uses thereof
|
|
WO2023281479A1
(en)
|
2021-07-09 |
2023-01-12 |
Bright Peak Therapeutics Ag |
Checkpoint inhibitors conjugated to il-2, and uses thereof
|
|
WO2023161857A1
(en)
|
2022-02-23 |
2023-08-31 |
Bright Peak Therapeutics Ag |
Bifunctional cytokine compositions
|
|
CN116036243B
(zh)
*
|
2022-04-20 |
2026-03-24 |
北京大学宁波海洋药物研究院 |
受体偏向的peg化il-2变体组合及其应用
|
|
US20240417436A1
(en)
|
2023-01-11 |
2024-12-19 |
Bright Peak Therapeutics Ag |
Conditionally activated immunocytokines and methods of use
|
|
WO2024150175A1
(en)
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Conditionally activated proteins and methods of use
|